Elevance Health Sets Ambitious 2026 Goals Amid Medicare and Medicaid Pressures

Elevance Health has outlined its financial and operational targets for 2026, setting an adjusted diluted earnings per share (EPS) guidance of at least $25.50. The company, led by CEO Gail Boudreaux, remains focused on improving healthcare outcomes while managing costs and accessibility.

Under Boudreaux's leadership, the firm plans to strengthen care coordination and simplify user experience. However, it anticipates challenges, including a decline in Medicare Advantage membership and a negative Medicaid operating margin.

Gail Boudreaux, President and CEO of Elevance Health, has over 30 years of experience in the healthcare sector. Before joining Elevance, she served as CEO of UnitedHealthcare and held executive roles at Health Care Service Corporation and Aetna Inc. Her confidence in the company's future stems from its diversified platform and Whole Health approach.

For 2026, Elevance expects operating revenue to drop in the low single-digit percent range. Medicare Advantage membership is projected to fall by a high teens percentage, while the Medicaid operating margin is forecasted at around negative 1.75%. Despite these pressures, the company maintains an enterprise margin target of 5%-6%.

The firm plans to allocate roughly $2.3 billion for share repurchases in 2026. It will also adopt a more cautious stance on mergers and acquisitions, reflecting a conservative approach to expansion. Key priorities include reducing complexity in healthcare delivery and enhancing care coordination for better patient outcomes.

Elevance Health's 2026 outlook balances financial discipline with strategic investments in care improvement. The company's adjusted EPS guidance, share repurchase plans, and cautious M&A strategy highlight its focus on stability. Meanwhile, challenges in Medicare Advantage and Medicaid margins will require ongoing attention.